BMLL

Bio Medica Laboratories Limited

Listed company · ISIN INE1BKA01015 · NSE SM · FV ₹10
Last price
₹160
-2.74%today
What this company does

Bio Medica Laboratories Limited is a listed company. It booked ₹43 cr of revenue in its latest half year (H2 FY26) and kept 27.3% of sales as profit.

62out of 100
Equitytale Health Score
Mixed

Healthier than 62% of listed companies we score, on the 5 of 6 measures we could read for it. Each measure is ranked against the 2,335–2,886 companies that reported it.

Measures financial condition, not whether to buy. Learn what this score means · How this is calculated

Price momentum
neutral
RSI (14)
51

At close. Not part of the score.

Profitability & returns97

How much profit it earns on the money it employs

Balance sheet34

How much it owes, and whether earnings cover the interest

Cash quality21

Whether reported profit actually arrives as cash

Valuation59

What today's price implies, against our models or its peers

Governance & risk100

How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure

Not measurable for this company: growth & consistency. Those pillars are left out of the score rather than counted as zero.

Is this company doing well?
not investment advice
A mixed picture
Strengths
✓ Makes a profit
✓ Strong 27% net margin
✓ Promoters hold 68%
✓ No promoter shares pledged
✓ Strong 136% return on equity
Watch-outs
! Carries high debt (D/E 2.3)

What if I invest in BMLL?

Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.

You would put in
₹12.00 lakh
120 instalments
At 10% a year, it would become
₹20.15 lakh

The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.

Key ratios · latest half year + price
₹160▼ -2.74%
latest close · 2026-10-01
52-wk low ₹13551 sessions so far52-wk high ₹181
Is it cheap or expensive?
What you pay for the profits, book value and cash flow. Higher isn't automatically worse — it can signal faster growth.
P/E ratio6.2Low
LowAverageHigh
P/B ratio8.45High
Below bookModerateHigh
EV / EBITDA5.0Low
LowAverageHigh
How good is the business?
How much profit it earns from its money and its sales.
Return on equity135.9%Strong
WeakFairStrong ▸15%
Return on capital68.4%Strong
WeakFairStrong
Net margin27.3%Strong
ThinDecentStrong
EBITDA margin43.0%Healthy
ThinDecentHealthy
Is it financially safe?
How much it owes, and whether it can comfortably cover it.
Debt to equity2.31High
LowModerateHigh ▸1
Interest cover8.2×Strong
RiskyOkayStrong ▸5×
Current ratio2.85Ample
Tight ◂1HealthyAmple
More figures
Market cap
₹146 cr
Book value
₹19
EPS
₹12.95
latest half year
Net debt
₹40 cr
owes more than its cash
Enterprise value
₹186 cr
EBITDA
₹37 cr
annualised
EBIT
₹37 cr
annualised
Operating margin
43.0%
Return on assets
32.1%
Earnings yield
16.24%
P/S
1.70
Sales / share
₹93.9
Tax rate
26.9%
Face value
₹10
Shares
0.9 cr
Working capital
₹35 cr
Current assets
₹55 cr
Current liabilities
₹19 cr
Delivery %
85.7%
Strong / safeFairWeak / riskyValuation — a level, not good/badBands are general rules of thumb, not advice.

P/E, ROE, ROCE and margins are annualised from the latest half year; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-10-01.

Worth vs price · from the exchange filings
not investment advice
Hard to value confidentlyLow confidence
Too few reliable models — the filings don't support two independent estimates of value.
Models span ₹121–₹121, midpoint ₹121

An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.

P&L · H2 FY26 (consolidated)
Revenue from Operations₹43 cr
Other Income₹2.3 L
Total Income₹43 cr
Cost of Materials₹18 cr
Purchases of Stock-in-Trade₹47.2 L
Inventory Change (±)₹-1 cr
Employee Benefit Expense₹3 cr
Finance Costs₹2 cr
Other Expenses₹3 cr
Total Expenses₹27 cr
Profit before Tax₹16 cr
Tax Expense₹4 cr
Net Profit₹12 cr
Net margin on total income27.3%
Where the money goes · H2 FY26
% of total income
Materials + stock-in-trade₹17 cr40.7%
Employee benefit expense₹3 cr7.1%
Finance costs₹2 cr5.2%
Other expenses₹4 cr9.5%
Tax expense₹4 cr10.2%
Profit for the period₹12 cr27.4%
Total income ₹43 cradds up to ₹100 ✓
Balance sheet & cash flow · as of Mar 2026
High debt
Total assets
₹73 cr
Shareholder equity
₹17 cr
parent shareholders
Total debt
₹40 cr
Cash
₹10.4 L
Who owns it · 2026-05-28
No pledge
Promoter
67.7%
FII / Foreign
0.3%
DII / Domestic
2.3%
Retail / others
29.7%
Smart-money activity
Bulk / block deals
SoldMAHABIR TRADEVENTURES LLP · NSE1.18 L @ ₹159.619 Aug 26
SoldRATHOD MANOJ CHHAGANLAL HUF · NSE91,000 @ ₹156.3618 Aug 26
BoughtRATHOD MANOJ CHHAGANLAL HUF · NSE46,000 @ ₹156.3718 Aug 26
What shareholders were asked to approve

A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.

Yearly shareholder meeting · 28 Sep 2026
See the official result
1
To receive, consider and adopt the Audited Financial Statement of the company for the financial year ended on March 31, 2026 including the Balance Sheet as at March 31, 2026, the Statement of Profit and Loss Accounts and Cash flow statement for the year ended on that date along with reports of the Board of Director’s and the Auditor’s thereon.
Backed by 100% of shareholders other than promotersneeded 50%
19.84 L votes for, 0 against · 0% of mutual funds and other big investors said no
2
To appoint Mr. Mukesh Mehta (DIN: 03187420) director who retires by rotation in terms of section 152 of the companies act, 2013 and being eligible, offers himself for re-appointment.
Promoters had a personal stake in this
Backed by 100% of shareholders other than promotersneeded 50%
19.84 L votes for, 0 against · 0% of mutual funds and other big investors said no
3
Appointment of Secretarial Auditor And Fix Their Remuneration.
Backed by 100% of shareholders other than promotersneeded 50%
19.84 L votes for, 0 against · 0% of mutual funds and other big investors said no
4
Increase in limit of total shareholding of all Registered Foreign Portfolio Investors (FPIs) / Registered Foreign Institutional Investors (FIIs) put together up to 49% of the paid-up Equity Share Capital of the Company.
Backed by 100% of shareholders other than promotersneeded 75%
19.84 L votes for, 0 against · 0% of mutual funds and other big investors said no

Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.

Who controls this company, and what it pays them

Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.

The promoter group — 23 named members
owning 67.7% between them · as of 2026-05-28
MUKESH MEHTA33.85%
PRADEEP MEHTA33.85%
ANJU MEHTAno shares
ARVIND MEHTAno shares
BABULAL HAGAMILAL JAINno shares
Bio Medica Parenteralsno shares
DHARVI MEHTAno shares
GARIMA MEHTAno shares

Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.

How the stock has moved · adjusted for splits & bonuses
Data from primary exchange filings · analysis tool, not investment advice.